Duval X - Search Results

1

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.

Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, Michailidis E, Hoffmann HH, Eto S, Garcia-Prat M, Bizien L, Parra-Martínez A, Yang R, Haljasmägi L, Migaud M, Särekannu K, Maslovskaja J, de Prost N, Tandjaoui-Lambiotte Y, Luyt CE, Amador-Borrero B, Gaudet A, Poissy J, Morel P, Richard P, Cognasse F, Troya J, Trouillet-Assant S, Belot A, Saker K, Garçon P, Rivière JG, Lagier JC, Gentile S, Rosen LB, Shaw E, Morio T, Tanaka J, Dalmau D, Tharaux PL, Sene D, Stepanian A, Megarbane B, Triantafyllia V, Fekkar A, Heath JR, Franco JL, Anaya JM, Solé-Violán J, Imberti L, Biondi A, Bonfanti P, Castagnoli R, Delmonte OM, Zhang Y, Snow AL, Holland SM, Biggs C, Moncada-Vélez M, Arias AA, Lorenzo L, Boucherit S, Coulibaly B, Anglicheau D, Planas AM, Haerynck F, Duvlis S, Nussbaum RL, Ozcelik T, Keles S, Bousfiha AA, El Bakkouri J, Ramirez-Santana C, Paul S, Pan-Hammarström Q, Hammarström L, Dupont A, Kurolap A, Metz CN, Aiuti A, Casari G, Lampasona V, Ciceri F, Barreiros LA, Dominguez-Garrido E, Vidigal M, Zatz M, van de Beek D, Sahanic S, Tancevski I, Stepanovskyy Y, Boyarchuk O, Nukui Y, Tsumura M, Vidaur L, Tangye SG, Burrel S, Duffy D, Quintana-Murci L, Klocperk A, Kann NY,… See abstract for full author list ➔ Bastard P, et al. Among authors: duval x. Sci Immunol. 2021 Aug 19;6(62):eabl4340. doi: 10.1126/sciimmunol.abl4340. Sci Immunol. 2021. PMID: 34413139 Free PMC article.

2

[Cutaneous signs of Rickettsia and related microorganisms].

Duval X, Chosidow O, Tissot-Dupont H, Raoult D, Frances C. Duval X, et al. Rev Med Interne. 1998 Aug;19(8):548-57. doi: 10.1016/s0248-8663(99)80022-8. Rev Med Interne. 1998. PMID: 9775070 Review. French.

3

[Long-term immunologic response in HIV-infected patients with CD4 cell counts </= 50/mm3 when initiating protease inhibitor therapy].

Le Moing V, Eid Z, Ecobichon JL, Duval X, Longuet P, Elbim C, Brun-Vezinet F, Leport C, Vilde JL. Le Moing V, et al. Among authors: duval x. Ann Med Interne (Paris). 2001 Feb;152(1):11-4. Ann Med Interne (Paris). 2001. PMID: 11240420 French.

4

Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir.

Duval X, Lamotte C, Race E, Descamps D, Damond F, Clavel F, Leport C, Peytavin G, Vilde JL. Duval X, et al. Antimicrob Agents Chemother. 2002 Feb;46(2):570-4. doi: 10.1128/AAC.46.2.570-574.2002. Antimicrob Agents Chemother. 2002. PMID: 11796381 Free PMC article.

5

Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.

Joly V, Descamps D, Peytavin G, Touati F, Mentre F, Duval X, Delarue S, Yeni P, Brun-Vezinet F. Joly V, et al. Among authors: duval x. Antimicrob Agents Chemother. 2004 Jan;48(1):172-5. doi: 10.1128/AAC.48.1.172-175.2004. Antimicrob Agents Chemother. 2004. PMID: 14693536 Free PMC article.

6

Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.

Duval X, Peytavin G, Albert I, Bénoliel S, Ecobichon JL, Brun-Vézinet F, Mentré F, Leport C, Vildé JL. Duval X, et al. HIV Med. 2004 Jul;5(4):307-13. doi: 10.1111/j.1468-1293.2004.00226.x. HIV Med. 2004. PMID: 15236622 Free article.

7

Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1.

Breton G, Alexandre M, Duval X, Prie D, Peytavin G, Leport C, Vildei JL. Breton G, et al. Among authors: duval x. Scand J Infect Dis. 2004;36(6-7):527-8. doi: 10.1080/00365540310016169. Scand J Infect Dis. 2004. PMID: 15307594

8

Maintenance therapy with cotrimoxazole for toxoplasmic encephalitis in the era of highly active antiretroviral therapy.

Duval X, Pajot O, Le Moing V, Longuet P, Ecobichon JL, Mentre F, Leport C, Vilde JL. Duval X, et al. AIDS. 2004 Jun 18;18(9):1342-4. doi: 10.1097/00002030-200406180-00016. AIDS. 2004. PMID: 15362670

9

Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort.

Duval X, Mentré F, Lamotte C, Chêne G, Spire B, Dellamonica P, Panhard X, Salmon D, Raffi F, Peytavin G, Leport C; APROCO Study Group. Duval X, et al. Ther Drug Monit. 2005 Feb;27(1):63-70. doi: 10.1097/00007691-200502000-00013. Ther Drug Monit. 2005. PMID: 15665749 Clinical Trial.

10

Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir/ritonavir combination.

Duval X, Peytavin G, Breton G, Ecobichon JL, Descamps D, Thabut G, Leport C. Duval X, et al. AIDS. 2007 Jan 2;21(1):106-8. doi: 10.1097/QAD.0b013e3280118486. AIDS. 2007. PMID: 17148976

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

436 results

Search Page